Literature DB >> 2853458

Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood.

J Harenberg1, C Giese, C E Dempfle, G Stehle, D L Heene.   

Abstract

A method for determination of antifactor Xa-like activity in capillary whole blood obtained from the fingertip is described, which employs the Heptest coagulation assay. Values obtained with capillary whole blood are compared to values of corresponding plasma and venous whole blood samples. Normal values in plasma, venous whole blood, and capillary blood from the fingertip were 17.1 +/- 2.1, 10.0 +/- 1.3 and 10.4 +/- 1.3 sec, respectively. The intraindividual coefficients of variations range from 0.4 to 1.8% in all assays. The day to day coefficient of variation of normal values ranged between 0.8 and 2.0% for all assays. The within assay coefficients of variation ranged from 3.0 to 7.7% for whole blood samples and from 1.5 to 2.2% for plasma samples after addition of no, 0.2 or 1.0 units of normal or LMW heparin to the samples. After administration of heparin or LMW heparin in healthy persons the coagulation values of the different coagulation assay systems displayed coefficients of correlation between r = 0.87 and r = 0.95. Correlation coefficients between the coagulation tests and the S 2222 chromogenic substrate method ranged from r = 0.77 to r = 0.92. In patients, who received LMW heparin for prophylaxis of thromboembolism the coagulation assay correlated between r = 0.78 and 0.92. The coagulation assays and the S 2222 method displayed coefficients of correlation between r = 0.74 and r = 0.83. The data indicate that Heptest sensitively measures antifactor Xa-like activity in capillary whole blood as well as venous whole blood samples containing low quantities of heparin or LMW heparin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2853458

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

Review 1.  Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.

Authors:  Job Harenberg; Ingrid Jörg; Yvonne Vukojevic; Gerd Mikus; Christel Weiss
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

2.  Hepatic uptake of a modified low molecular weight heparin in rats.

Authors:  G Stehle; E A Friedrich; H Sinn; A Wunder; J Harenberg; C E Dempfle; W Maier-Borst; D L Heene
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.